SCHEMBL3765281

SCHEMBL3765281

CN(CCN)C(=O)c1ccn[c]c1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.47
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.36
CARM1 Q86X55 1/20 0.36
PRMT6 Q96LA8 1/20 0.36
PRMT8 Q9NR22 1/20 0.36
NTRK1 P04629 3/20 0.35
MAPT P10636 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
AOC3 Q16853 1/20 0.34
CSNK2A2 P19784 2/20 0.34
CSNK2A1 P68400 2/20 0.34
KDR P35968 1/20 0.34
CSNK2B P67870 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3763681 0.88 KMT2A (0.42) CHEK1KMT2AMEN1ALDH1A1HPGD
SCHEMBL3769349 0.86 TRPM8 (0.47) KMT2AMEN1ALDH1A1HPGDMAPT
SCHEMBL3758759 0.83 KMT2A (0.50) KMT2AMEN1ALDH1A1HPGDTRPM8
SCHEMBL3764668 0.80 HPGD (0.49) ALDH1A1HPGDMAPT
SCHEMBL3759975 0.78 TRPM8 (0.37) KMT2AMEN1ALDH1A1HPGDTRPM8
SCHEMBL3761229 0.75 SMN1; SMN2 (0.40) KMT2AALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL3761415 0.75 BCAT2 (0.46) KMT2AMEN1ALDH1A1HPGDMAPT
SCHEMBL3759347 0.75 ALDH1A1 (0.41) ALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL3769036 0.72 GAA (0.41) CHEK1ALDH1A1HPGDMAPT
SCHEMBL3761439 0.71 TSHR (0.51) KMT2AMEN1ALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA CHEK1 102/4885KMT2A 2175/4885MEN1 2762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.